4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer by Marchi, T. (Tommaso) de et al.
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 2 4e3 9ava i lab le a t www.sc ienced i rec t . com
ScienceDirect
www.elsevier .com/locate/molonc4-protein signature predicting tamoxifen treatment outcome in
recurrent breast cancerTommaso De Marchia,h,*, Ning Qing Liua,1, Cristoph Stinglb,
Mieke A. Timmermansa, Marcel Smida, Maxime P. Looka, Mila Tjoaa,
Rene B.H. Braakmana,h, Mark Opdamc, Sabine C. Linnc, Fred C.G.J. Sweepd,
Paul N. Spane, Mike Kliffenf, Theo M. Luiderb, John A. Foekensa,
John W.M. Martensa,g, Arzu Umara
aDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Wytemaweg 80,
P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands
bDepartment of Neurology, Erasmus MC, University Medical Center, Wytemaweg 80, P.O. Box 2040, 3000 CA,
Rotterdam, The Netherlands
cDivision of Medical Oncology, Netherlands Cancer Institute e Antoni van Leeuwenhoek Hospital, Plesmanlaan 121,
1066 CX, Amsterdam, The Netherlands
dDepartment of Laboratory Medicine, Radboud University Medical Center, PO Box 9101, NL-6500 HB, Nijmegen,
The Netherlands
eDepartment of Radiation Oncology, Radboud University Medical Center, PO Box 9101, NL-6500 HB, Nijmegen,
The Netherlands
fDepartment of Pathology, Maasstad Hospital, Maasstadweg 21, 3079 DZ, Rotterdam, The Netherlands
gCancer Genomics Center Netherlands, Amsterdam, The Netherlands
hPostgraduate School of Molecular Medicine, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsA R T I C L E I N F O
Article history:
Received 30 June 2015
Accepted 23 July 2015
Available online 7 August 2015Abbreviations: MS, mass spectrometry; IH
LFQ, label-free quantification; ER, estrogen
spectrometry; SD, standard deviation; WTL
free interval; PEP, posterior error probability
e Antoni van Leeuwenhoek Hospital; Radbo
positive predicted value; NPV, negative pre
remission; NC, no change; PD, progressive d
area under the curve; LC-MS, liquid chroma
* Corresponding author. Tel.: þ31 10 704431;
E-mail addresses: t.demarchi@erasmusm
mermans@erasmusmc.nl (M.A. Timmerman
mail.com (M. Tjoa), r.braakman@erasmusm
labgk.umcn.nl (F.C.G.J. Sweep), P.Span@rther
(T.M. Luider), j.foekens@erasmsumc.nl (J.A.
1 Present address: Department of Molecula
Life Sciences, P.O. Box 9101, 6500 HB, Nijme
http://dx.doi.org/10.1016/j.molonc.2015.07.00
1574-7891/ª 2015 The Authors. Published by
access article under the CC BY-NC-ND licenA B S T R A C T
Estrogen receptor (ER) positive tumors represent the majority of breast malignancies, and
are effectively treated with hormonal therapies, such as tamoxifen. However, in the recur-
rent disease resistance to tamoxifen therapy is common and a major cause of death. In
recent years, in-depth proteome analyses have enabled identification of clinically usefulC, immunohistochemistry; LCM, laser capture microdissection; TMA, tissue micro-array;
receptor; SRM/MRM MS, selected reaction monitoring/multiple reaction monitoring mass
, whole tissue lysate; PgR, progesterone receptor; TTP, time to progression; DFI, disease
score; EMC, Erasmus MC, University Medical Center; NKI-AVL, Netherlands Cancer Institute
udUMC, Radboud University Medical Center; HR, hazard ratio; CI, confidence interval; PPV,
dicted value; ROC, receiver operating characteristic; CR, complete remission; PR, partial
isease; SD, stable disease; PEN, polyethylene naphthalate; IQR, interquartile range; AUC,
tography mass spectrometry; IPA, ingenuity pathway analysis.
fax: þ31 10 7044377.
c.nl (T. De Marchi), n.liu@ncmls.ru.nl (N.Q. Liu), c.stingl@erasmusmc.nl (C. Stingl), a.tim-
s), m.smid@erasmusmc.nl (M. Smid), m.look@erasmusmc.nl (M.P. Look), milatjoa@hot-
c.nl (R.B.H. Braakman), m.opdam@nki.nl (M. Opdam), s.linn@nki.nl (S.C. Linn), f.sweep@
.umcn.nl (P.N. Span), KliffenM@maasstadziekenhuis.nl (M. Kliffen), t.luider@erasmusmc.nl
Foekens), j.martens@erasmusmc.nl (J.W.M. Martens), a.umar@erasmsumc.nl (A. Umar).
r Biology, Radboud University Nijmegen, Faculty of Science, Radboud Institute for Molecular
gen, The Netherlands.
4
Elsevier B.V. on behalf of Federation of European Biochemical Societies. This is an open
se (http://creativecommons.org/licenses/by-nc-nd/4.0/).
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 2 4e3 9 25Keywords:Breast cancer
Proteomics
Tamoxifen resistance
Biomarker
Mass spectrometrybiomarkers, particularly, when heterogeneity in complex tumor tissue was reduced using
laser capture microdissection (LCM). In the current study, we performed high resolution
proteomic analysis on two cohorts of ER positive breast tumors derived from patients
who either manifested good or poor outcome to tamoxifen treatment upon recurrence. A
total of 112 fresh frozen tumors were collected from multiple medical centers and divided
into two sets: an in-house training and a multi-center test set. Epithelial tumor cells were
enriched with LCM and analyzed by nano-LC Orbitrap mass spectrometry (MS), which
yielded >3000 and >4000 quantified proteins in the training and test sets, respectively.
Raw data are available via ProteomeXchange with identifiers PXD000484 and PXD000485.
Statistical analysis showed differential abundance of 99 proteins, of which a subset of 4
proteins was selected through a multivariate step-down to develop a predictor for tamox-
ifen treatment outcome. The 4-protein signature significantly predicted poor outcome pa-
tients in the test set, independent of predictive histopathological characteristics (hazard
ratio [HR] ¼ 2.17; 95% confidence interval [CI] ¼ 1.15 to 4.17; multivariate Cox regression
p value ¼ 0.017). Immunohistochemical (IHC) staining of PDCD4, one of the signature pro-
teins, on an independent set of formalin-fixed paraffin-embedded tumor tissues provided
and independent technical validation (HR ¼ 0.72; 95% CI ¼ 0.57 to 0.92; multivariate Cox
regression p value ¼ 0.009). We hereby report the first validated protein predictor for
tamoxifen treatment outcome in recurrent ER-positive breast cancer. IHC further showed
that PDCD4 is an independent marker.
ª 2015 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction amounts due to the fact that only a limited number of cellsER positive tumors constitute the majority of all breast malig-
nancies. Tamoxifen therapy has been shown to significantly
improve survival and cure of patientswith primary ER positive
breast tumors, but upon recurrence about half of the patients
show intrinsic resistance, while those initially respondingwill
ultimately develop acquired resistance (Cardoso et al., 2012;
Milani, 2014). The need for biomarkers capable of determining
mechanisms of resistance has led to the development of
several predictive signatures, though none has been intro-
duced in the clinic so far (Beelen et al., 2012). With the recent
advancements in MS techniques, in-depth quantification of
the human proteome has become possible and the ability of
measuring protein abundance over a broad dynamic range
has established proteomics as a robust tool for biomarker dis-
covery (Drabovich et al., 2014; Kim et al., 2014; Wilhelm et al.,
2014). The proteomic analysis of tissue specimens is, however,
hindered by their heterogeneity, which alters protein abun-
dance dynamic range. Furthermore, the presence of stromal
and infiltrating cells adds another layer of complexity by
hampering accurate protein quantitation of target epithelial
tumor cells (Kondo, 2014). To address this issue, LCM offers
a robust cell sub-population enrichment technique, allowing
accurate downstream analysis of morphologically heteroge-
neous specimens (Emmert-buck et al., 1996; Vogel et al.,
2007). Genomic and proteomic analyses of LCM derived mate-
rial showed the feasibility of this technique in molecular
profiling studies and pointed out its efficacy in studying dis-
ease associated signaling pathways when compared to whole
tissue analyses (Cheng and Zhang, 2013; Sereni et al., 2015; Xu,
2010; F. Yang et al., 2006). LCM yields sub-microgram proteincan be dissected from each sample. In the light of this,
coupling LCM enrichment to chemical labeling methods
would require extensive sample preparation and workflow
optimization, which would be unsuitable in the analysis of
large sample sets. Label-fee quantification (LFQ) software al-
gorithms have demonstrated to be accurate tools in the quan-
titation of proteins, allowing high yield identification and
reliable quantitation of measured peptides even from minute
amount of analyzed specimens (Cox and Mann, 2008; Megger
et al., 2013). We have optimized a tissue proteomic pipeline for
biomarker discovery coupling LCM cell enrichment to high
resolution LC-MS and LFQ, capable of quantifying more than
3000 proteins from only 4000 dissected epithelial cells
(Braakman et al., 2012; Liu et al., 2012). Using this workflow,
we recently developed and validated a prognostic protein
signature for triple negative breast cancer (Liu et al., 2014).
Despite our workflow has demonstrated to be a robust meth-
odology for the discovery of cancer biomarkers, application of
shotgun proteomics in clinical diagnostics remains problem-
atic due to the extensive and time consuming sample prepara-
tion required. In this perspective, IHC or selected reaction
monitoring/multiple reaction monitoring (SRM/MRM) MS
may be more suitable biomarker verification techniques that
do not require extensivemethod optimization or sample prep-
aration (Whiteaker et al., 2011). Although antibody specificity
and lack of accurate quantitation remain important issues,
IHC still remains a major technique in clinical diagnostics
and significantly requires less amount of optimization time
in comparison to ELISA or even SRM/MRM MS.
In this study we describe the development of a predictive
protein signature for tamoxifen resistance in ER positive
Figure 1 e Data analysis flow-chart and development of predictor for tamoxifen treatment outcome. Patients were divided into two independent
cohorts and separately measured by LC-MS. Proteomic data from training and test sets were analyzed separately in MaxQuant. Identified proteins
were filtered for reversed sequences and for Posterior Error Probability score (PEP< 0.05), intensities of commonly expressed proteins were
normalized using ComBat algorithm to minimize batch effects, and filtered for missing data (10 minimum observations for global proteomic
analysis and allowing 30% and 0% missing data in training and test set respectively for predictor generation). Student t test ( p value< 0.05) was
then used to assess differences in protein expression levels between good and poor outcome patients. A multivariate regression model was used to
obtain an optimal list of 4 proteins to be tested as a predictor of tamoxifen treatment outcome: CGN, G3BP2, PDCD4 and OCIAD1. The 4-
protein signature was confirmed in an external test set. Acronyms: EMC[ Erasmus MC, University Medical Center; NKI-AVL[Netherlands
Cancer Institute- Antoni van Leeuwenhoek hospital; RadboudUMC [ Radboud University Medical Center.
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high resolution LC-MS in the analysis of independent training
and test patient cohorts.We also provide further validation by
IHC analysis of signature proteins on an independent panel of
paraffin-embedded tissues captured in a tissue micro-array
(TMA).Table 1 e Patient and tumor characteristics.
Traininga Testa
EMC NKI-AVL RadboudUMC
All patients 56 (100) 41 (100) 15 (100)
Age
 55 years 15 (27) 12 (29) 1 (7)
> 55 years 41 (73) 29 (71) 14 (93)
Menopausal status
Premenopausal 10 (18) 11 (27) 0 (0)
Postmenopausal 46 (82) 30 (63) 15 (100)
Tumor size
T1 (2 cm) 12 (21) 20 (49) 5 (33)
T2 (2e5 cm) þ Tx 40 (72) 19 (46) 9 (60)
T3 (>5 cm) þ T4 4 (7) 2 (5) 1 (7)
Tumor differentiationb
Good/Moderate 13 (59) 29 (71) 8 (53)
Poor 33 (23) 12 (29) 4 (27)
Unknown 10 (18) 0 (0) 3 (20)
Disease free interval
 12 months 24 (43) 4 (10) 5 (33)
> 12 months 32 (57) 37 (90) 10 (67)
PgRc
Negative 9 (16) 17 (41) 11 (73)
Positive 44 (79) 24 (59) 4 (27)
Involved lymph nodes
0 31 (55) 24 (58) 6 (40)
 1 20 (36) 16 (39) 7 (47)
unknown 5 (9) 1 (3) 2 (13)
Dominant site of relapse
Loco-regional 8 (14) 4 (10) 0 (0)
Bone 26 (46) 12 (29) 6 (40)
Visceral 13 (24) 6 (15) 9 (60)
Bone and other 9 (16) 14 (34) 0 (0)
Unknown 0 (0) 5 (12) 0 (0)
Acronym: PgR: progesterone receptor.
a Data are reported as number (percentage).
b Histopathological characteristics were evaluated by local pathol-
ogists, according to standard clinical practice at time of sample
collection.
c Missing data not reported.2. Materials and methods
2.1. Sample sets
From an initial selection of 200 tissues collected from patients
that received tamoxifen as first line therapy we excluded tis-
sues with a low percentage of tumor cells (i.e. <40%; n ¼ 88;
Figure 1). A total of 112 ER positive fresh frozen primary breast
cancer tissue samples were then included in our sets: 56 from
Erasmus MC University Medical Center (EMC), Rotterdam
(years of surgery: 1981e1994), 41 from the National Cancer
Institute e Antoni van Leeuwenhoek hospital (NKI-AVL),
Amsterdam (1980e1996), and 15 from Radboud University
Medical Center (RadboudUMC), Nijmegen (1991e1996; Table
1). EMC derived samples constituted the training set, while
NKI-AVL and RadboudUMC provided an independent external
test set. ER positivity in tumor cytosols was assessed by quan-
titative biochemical assays (EMC), reverse-transcriptase
quantitative polymerase chain reaction (RadboudUMC), or
IHC (NKI-AVL). All patients underwent surgery of their pri-
mary tumor (conservative or non-conservative), developed
recurrent disease, and were treated with tamoxifen as first
line therapy. Due to lack of response data for a subset of spec-
imens, treatment outcome was defined based on time to pro-
gression (TTP): disease progression6months and>6months
after start of first line tamoxifen administration were defined
as poor and good outcome, respectively. The training set
comprised 24 and 32 patients who showed good and poor
outcome upon tamoxifen treatment, respectively. The test
set included tumors of 41 good and 15 poor outcome patients.
The NKI-AVL cohort did not contain stage IV tumors, while
such specimens were found in the EMC and RadboudUMC
sets. In addition, 2 tumor tissues of which clinical followup in-
formation was not available were used as LCM and whole tis-
sue lysate (WTL) controls. For biological replicates, both tumor
tissues were subjected to 4 rounds of LCM. Of one of these, a
WTLwas prepared from one sample and digested in triplicate.
In addition, a total of 447 formalin-fixed and paraffin-
embedded tissues collected from EMC and regional hospitals
were comprised in a tissue micro-array. For further analyses,
we included only ER positive tumors and patients who did not
receive hormonal adjuvant therapy. Patients with a revised
histology that showed no tumor, or patients with a progres-
sion within 3 weeks were excluded as well, leading to a total
of 408 ER positive tissues from patients treated with tamox-
ifen as first-line therapy for recurrent disease (Supplemental
Table 1). Response data were collected according to the stan-
dard International Union Against Cancer criteria (Hayward
and Carbone, 1977). In this set, 11 (2.7%) and 51 (12.5%) pa-
tients respectively showed complete (CR) and partial remis-
sion (PR). Two hundred and five (50.3%) patients showed nochange (NC) of disease, of whom 170 (41.7%) showed NC >6
months (defined as stable disease, SD) while 35 (8.6%) showed
NC 6 months after start of therapy. Progressive disease (PD)
was observed in 141 (34.6%) patients. Clinical benefit was
defined as CR þ PR þ SD patients (n ¼ 232; 57%), while objec-
tive response was defined as CR þ PR only (n ¼ 62; 15%).
This retrospective study used coded primary tumor tissues,
in accordance with the Code of Conduct of the Federation of
Medical Scientific Societies in the Netherlands (http://
www.federa.org/codes-conduct). Reporting Recommenda-
tions for Tumor Marker Prognostic Studies were followed
where possible (Altman et al., 2012).2.2. Laser capture microdissection
All tissue samples were cut into 8 mm cryo-sections, and
collected on UV-sterilized polyethylene naphthalate (PEN)
coated glass slides (Carl ZeissMicrosystems GmbH, G€ottingen,
Germany) for downstream LCM. In addition, 5 mm sections
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toxylin and eosin dyes for histological evaluation. Sections on
PEN slides were dehydrated with 95% ethanol and immedi-
ately stored at 80 C, until further processing. Prior to LCM,
PEN slides were thawed at room temperature and subse-
quently stained with hematoxylin as follows: distilled water,
hematoxylin, distilled water, 50% ethanol, 70% ethanol, 95%
ethanol, 100% ethanol, 100% ethanol. During dehydration
steps Halt Protease Inhibitor Cocktail (Thermo Fisher Scienti-
fic Inc, Rockford, IL, USA) at a 1:100 v/v concentration was
added in order to prevent proteolytic degradation of proteins.
An area of approximately 500,000 mm2 (w4000 tumor cells) was
collected from each tissue using a photo-activated localiza-
tion microscopy Micro Beam device and gathered in an opa-
que adhesive cap (Carl Zeiss Microsystems GmbH,
G€ottingen, Germany). A volume of 20 ml of 0.1% w/v Rapigest
surfactant (Waters Corporation, Milford, MA, USA) in 50 mM
ammonium bicarbonate solution was used to transfer the
collected LCM samples into LoBind Eppendorf tubes (Eppen-
dorf AG, Hamburg, Germany). Tissue containing buffer was
immediately frozen after collection and stored at 80 C.
2.3. Protein digestion
LCM collected material was disrupted in a horn sonifier bath
using an Ultrasonic Disruptor Sonifier II (Bransons Utrasonics,
Danbury, CT, USA) at 70% amplitude. Proteins were denatured
at 95 C, reducedwith 100mMDTT for 30min at room temper-
ature, and alkylated in the dark with 300 mM iodoacetamide
for 30 min at room temperature. Samples were then digested
for 4 h at 37 C after addition of MS grade trypsin at a 1:4
enzyme-protein ratio (i.e. 100 ng/ml). Samples were acidified
with TFA, and spun down at 14,000 RPM. Supernatants were
collected and transferred to HPLC vials (SigmaeAldrich Corpo-
ration, St. Louis, MO, USA).
2.4. High resolution MS
Mass spectrometry measurements were performed with a
nano liquid chromatography system (Ultimate 3000, Dionex,
Amsterdam, The Netherlands) coupled online to a linear Ion
Trap e Orbitrap XL mass spectrometer (Thermo Electron,
Bremen, Germany). Samples were first loaded on a trap col-
umn (PepMap C18, 300 mm ID  5 mm length, 5 mm particle
size, 100 A pore size; Dionex), then washed and desalted in
0.1% TFA acidified water. Trap column and analytical column
(PepMap C18, 75 mm ID  50 cm, 3 mm particle size and 100 A
pore size; Dionex) were then coupled and peptideswere eluted
in a 3 h binary gradient (flow: 300 nl/min; mobile phase A: 2%
acetonitrile and 0.1% formic acid in H2O; mobile phase B: 80%
acetonitrile and 0.08% formic acid). Gradient was run as fol-
lows: 0%e25% mobile phase B for 2 h, increase to 50% mobile
phase B in 1 h. For ESI, metal-coated nano ESI emitters (New
Objective, Woburn, MA) were used and a spray voltage of
1.6 kV was applied. High-resolution scan was acquired from
400 to 1800 Th and was used for MS detection. Automatic
gain was set at 106 ions and lock mass was set at
445.120025 u protonated with (Si(CH3)2O)6. The 5 most intense
peaks in full scan were selected and fragmented by collision
induced dissociation (CID) applying 35% normalized collisionenergy and detected in the ion trap. Ions falling out of the
5 ppm window or for which precursor intensity fell below
1.5 signal-to-noise ratio during 10 scans were excluded.
2.5. Protein identification and quantification
A total of 112 sampleswere analyzed by LTQ-Orbitrap XLMS,
together with 4 biological LCM replicates of control samples,
and of which one wasmeasured with a triplicate of its match-
ing WTL. MS spectra of the training and test cohorts were
generated and analyzed separately with a time interval of
two years. Orbitrap.RAW files derived from MS analyses
were imported and analyzed in MaxQuant (version 1.2.2.5)
(Cox and Mann, 2008), using Andromeda peptide search en-
gine (Cox et al., 2011). Analysis of spectrawas performed using
the following options: acetylation of the N-terminus and
oxidation of methionine were selected as variable modifica-
tions, multiplicity was set to 1. FASTA file used for protein
search was UniProt-SwissProt human canonical database
(version 2012-09, human canonical proteome; 20.243 identi-
fiers). Minimal peptide length was set to 7 amino acids, match
between runs and LFQ options were selected and kept as
default. Other options were kept as default (e.g. fixed peptide
modifications: carbamidomethylation; false discovery
rate ¼ 0.01). For further data analysis, “ProteinGroups.txt”
file was imported into Microsoft Excel and protein identifiers
were filtered based on PEP score (cutoff <0.05). Contaminants
and reversed sequences were excluded. LFQ intensities for
each sample were selected and each value was Log10 trans-
formed. Protein intensities from training and test sets were
then normalized using ComBat (Johnson et al., 2007) algorithm
in R free software, allowing 10 minimum observations for
whole dataset analysis. A second protein list was generated
allowing 30% missing data points in the training set and
none in the test set for predictor development. LCM and
WTL control samples were not included in the ComBat
normalization procedure due to the lower amount of identi-
fied and quantified proteins. Coefficients of variations of
Log10 transformed MS data were calculated according to the
following formula (Bland and Altman, 1996):
CV ¼ 10ðStandard deviationÞ  1
Pearson correlation coefficients between measurements of
LCM and WTL replicates were calculated in Perseus (Max
Planck Institute for Biochemistry, Muenchen, Germany). The
MS proteomic data have been deposited to the ProteomeX-
change Consortium (http://proteomecentral.proteomexchan-
ge.org) via the PRIDE partner repository (Vizcaıno et al., 2013)
with dataset identifiers PXD000484 and PXD000485.
2.6. Tissue micro-array
TMA was prepared using an ATA 27 (Beecher Instruments,
Sun Prairie,WI, USA). 408 paraffin-embedded primary, ER pos-
itive breast cancer tissues derived from patients treated with
first line tamoxifen upon recurrence were used to prepare
the TMA. Tissue cores of 0.6 mm were taken from each tissue
paraffin block and transferred in triplicate into a TMA recip-
ient block. For each tumor tissue sample, three different areas
of the tumor were taken as biological replicates. TMA slides
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Microsystems, Solms, Germany).
2.7. Immunohistochemistry
Paraffin-embedded tissues on glass slides were de-
paraffinized at 60 C, and remnants of paraffin were removed
by sequential washings in xylene (3  5 min). Re-hydration
was performed by washings through decreasing concentra-
tions of ethanol following with distilled water as follows:
100% ethanol (1  5 min, 2  2 min), 70% ethanol
(1  2 min), 50% ethanol (1  2 min), distilled water
(1  2 min). Slides were then incubated at 95 C for 40 min in
DAKO (Agilent Technologies Inc, Santa Clara, CA, USA) anti-
gen retrieval solution (pH 6) diluted 1:10 in MilliQ water,
cooled down to room temperature and washed with PBS
buffer 3 times for 5 min. Blocking solution consisting of 5%
BSA in PBS was added to the slides and incubated for
30 min. Primary antibodies were diluted in DAKO Antibody
Diluent, added to each slide and incubated for 1 h at room
temperature. Slides were then washed with PBS, and DAKO
Envision secondary antibody (Goat anti-Mouse-HRP and G
anti-R-HRP, 100 ml per slide) solution was added to each slide
and incubated for 45 min at room temperature. A washing cy-
cle with PBS was performed for 5 min and a 1:15 solution of
DABþ chromogen in antibody diluentwas added, following in-
cubation in the dark for 10 min. Slides were then washed in
tap water for 5 min, stained with hematoxylin/eosin for
1 min each and dehydrated again through sequential wash-
ings in 50%e70%e100% ethanol and xylene of 5 min each.
Cover glasses were mounted with Pertex and slides were left
to dry. TMA slides were stained for Programmed Cell Death
4 (PDCD4) protein (1:200), OCIAD1 (1:800), G3BP2 (1:50), and
CGN (1:25). Anti-PDCD4 mouse monoclonal (id: LS-B2949;
clone K4C1) and anti-OCIAD1 rabbit polyclonal (id: LS-B5046)
antibodies were purchased from Lifespan Technologies (Life-
span technologies Inc, Seattle, WA, USA), anti-G3BP2 rabbit
polyclonal (id: NBP1-82976) antibody was purchased from
Novus Biologicals (Novus Biologicals LLC, 8100 Littleton, CO,
USA), and anti-CGN rabbit polyclonal (HPA027657) antibody
was purchased from Sigma.
2.8. IHC staining analysis
Data from scored tissues were filtered for missing data and
adjuvant endocrine therapy, leading to a final list of 294 tissue
samples. PDCD4 antibody stained tissues were separately
scored for nuclear and cytoplasmic staining intensity (cate-
gories: negative, weak, moderate, strong) and percentage of
stained tumor cells (categories: 0%, 1e10%, 11e20%, 21e30%,
31e40%, 41e50%, 51e60%, 71e80%, 81e90%, 91e100%). CGN,
and OCIAD1 stained tissues were scored based on intensity
parameters only, while G3BP2 scoring included quantity levels
as well. TMAwas scored by two independent researchers, and
the average, consolidated scores of triplicate cores were used
for statistical analysis. Due to the fact that PDCD4 cytoplasmic
and nuclear stainings were co-expressed in the evaluated
TMA cores, these were merged in order to assess total
protein levels. PDCD4 nuclear and cytoplasmic scores were
numerically transformed and merged into a histo-score(Supplemental Table 2) according to formula:
Histo score ¼ ðnuclear quantity x nuclear intensityÞ
þ cytoplasmic intensity
Histo-score cutoff (i.e. 30) reflective of weak vs strong pro-
tein expression was used to stratify patient groups: low and
high PDCD4 protein expressing tumors displayed a histo-
score below (<) or above () the cutoff (Supplemental Table
3). PDCD4 cytoplasmic quantity was ranging only from 80%
to 90% so it was not included in the histo-score calculation
formula.2.9. Statistical analysis
Differences in clinical parameters between training and test
sets were evaluated by ManneWhitney U and Pearson c2 tests
(two sided tests). Commonly expressed proteins between the
two LCM sets and proteins quantified in WTL sample repli-
cates were annotated through DAVID (Huang and Lempicki,
2008; Huang et al., 2009) for organelle distribution using Swis-
sprot keyword database. Average abundance levels of these
proteins in all 112 measured samples were used to generate
a waterfall plot of protein abundance distribution.
Protein list used for predictor development was tested for
protein differential abundance between patient groups
through Student’s t-test (two sided, unequal variances
assumed). Hierarchical clustering was performed on all quan-
tified and differentially expressed proteins (t test p
value < 0.05), respectively (complete linkage; distance metric:
correlation-uncentered). Significant proteins in the training
set were submitted along with their fold changes and t test p
values to Ingenuity Pathway Analysis (IPA) network analysis
with the following settings: Data sources: all; Confidence:
high (predicted) and experimentally observed; species: hu-
man. Networkwas plotted using path designer (Ingenuity Sys-
tems, Redwood City, CA, USA).
In order to rule out possible indiscriminative identifiers,
the protein predictor was developed selecting the 38 most sig-
nificant proteins (univariate p value < 0.01) in the training set
and a Cox regression multivariate analysis was performed
with a step-down procedure, which involved iteratively
removing the least significant proteins (multivariate p
value 0.01) until all remaining proteins in themodel showed
a multivariate p value < 0.01. Each protein score (t value) was
then multiplied by its abundance, and values were then
summed for all proteins to obtain a patient score, which was
then coupled to outcome data. Each patient score was plotted
in a receiver operating characteristic (ROC) curve. Youden in-
dex (max of J ¼ Sensitivityþ Specificity1) was set as cutoff in
the training set and used to categorize patients in the test set.
Log-rank tests on the survival curves of predicted groups were
performed to assess significance of prediction. Association of
predictor proteins to TTP was assessed through Cox regres-
sion, correcting for patient and tumor characteristics. IHC
stainings were used to test for association with TTP, clinical
benefit and objective response in combination with clinical
parameters by Cox and logistic regression analyses, respec-
tively. Co-variables that were found not significant in univar-
iate regression analyses were excluded from multivariate
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ard ratios, odds ratios and confidence intervals were calcu-
lated in Stata (version 13.1; Stata Corp, College Station, TX,
USA).Figure 2 e Protein abundance levels in 112 ER positive breast cancer
samples. The waterfall plot shows mean protein abundance
distribution of 1.960 commonly expressed proteins. The mean
abundance of each quantified protein was calculated and plotted. The
30 least (blue) and most (red) abundant proteins are boxed in panel
(A) and enlarged in panel (B) and (C), respectively.3. Results
3.1. Analysis of patient cohorts
One hundred and twelve ER positive primary breast tumor tis-
sues, of which 56 comprised the training set and another 56
the test set, were processed according to our tissue prote-
omics workflow (Braakman et al., 2012; Liu et al., 2012) and
analyzed through high resolution MS.
Analysis of tumor and patient characteristics between the
training and test sets showed that age andmenopausal status
at start of tamoxifen therapy, lymph node status, and tumor
size were not significantly different. The test set contained a
higher proportion of poorly differentiated tumors (Pearson’s
c2 ¼ 21.19, p value < 0.001) compared to the training set.
Furthermore, patients in the test cohort had a median disease
free interval (DFI) of 51.4 months (range: 0e195 months),
which was significantly longer (ManneWhitney U ¼ 3.814,
p value < 0.001) than for patients in the training set (median:
16.4 months, range: 0e90.8 months). This can be attributed
to the lack of stage IV tumors in the NKI-AVL cohort, which
possibly contributed to the difference in DFI and grade be-
tween training and test set.
3.2. MS analysis of ER positive breast cancer
LCM discovery and test samples were analyzed along with 8
LCM replicates from 2 separate control tissues, and 3 technical
replicates of a control WTL. A total of 2215 proteins were
quantified in LCM control samples, and 1320 proteins in the
WTL sample replicates, with only 852 proteins quantified in
both LCM and WTL controls. Pearson correlation coefficients
between LCM samples ranged from 0.92 to 0.97 while it ranged
from 0.96 to 0.97 betweenWTL measurements (Supplemental
Figure 1A). Hierarchical clustering of LCM and WTL controls
showed grouping according to sample origin without miss-
classifications (Supplemental Figure 1B). Median coefficients
of variation of biological and technical replicates were
16.05% (interquartile range, IQR: 10.77e24.56) and 20.35%
(IQR: 11.55e34.28), respectively. Reproducibility of MS mea-
surements was defined as acceptable given the low number
of control samples replicate measurements.
A total of 3227 proteins were identified in the training set,
of which 3109 were quantified by LFQ. In the test set, 4278 pro-
teins were identified and 4061 proteins were quantified. LFQ
intensity values of 2741 proteins commonly expressed be-
tween the training and test set were normalized for batch dif-
ferences and filtered for missing data to generate two protein
lists: a 1960 protein list (10 minimum observations;
Supplemental Table 4) for general proteome analysis and an
845 protein list for predictor development (30% missing data
in training set and 0% missing data in test set; Supplemental
Table 5). From the analysis of 1960 expressed proteins, a
wide distribution of protein abundances was observed over 3orders of magnitude (Figure 2A). Interferon signaling related
(e.g. IFI16, IFIT5) and chaperone associated proteins (e.g.
DNAJC7, BAG1) displayed low overall abundance (Figure 2B),
while luminal epithelial specific (e.g. KRT18), metabolism
related (e.g. PKM, ATP5A1), and heat-shock (e.g. HSPD1,
HSPB1) proteins were found to be highly abundant
(Figure 2C). In the training set, CV was 14.10% (IQR:
10.22e18.78), whereas it was 13.86% (IQR: 10.33e18.57) in the
test set.
DAVID based annotation for subcellular compartment
showed that in the 112 breast cancer tissues the majority of
expressed proteins belonged to the nuclear (25.76%) and cyto-
plasmic (56.38%) compartments while the endoplasmic retic-
ulum (9.54%), Golgi apparatus (6.43%), mitochondria (12.65%),
plasma membrane (7.50%), and the extracellular matrix
(1.84%) comprised a lower amount of proteins. The smallest
group consisted of plasma proteins (0.46%; Figure 3A). The dis-
tribution of intensity levels of the 1320 proteins quantified in
the WTL control sample showed a similar dynamic range
but with increased variation, probably due to exclusion from
Figure 3 e Protein compartmentalization and abundance correlation analysis. Panel shows quantified protein abundance range per subcellular
compartment in the LCM enriched 112 ER positive tumors (A) and in WTL control replicates (B). Number of proteins per compartment and
percentages are displayed above the dot plot.
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cellular compartments showed a similar distribution of the
1320 identified proteins into subcellular compartments
compared to the 112 tissue set but with a notable enrichment
of extracellular matrix (e.g. COL1A1) and plasma proteins (e.g.
APOA1), which represented 7.19% and 6.89% of all quantified
proteins in this set, respectively. The minor contribution ofextracellular matrix and plasma proteins in the LCM samples
suggests that LCM indeed resulted in highly enriched epithe-
lial tumor cell fractions.
Distribution of intensities of organelle specific proteins
showed comparable average levels of expression, therefore
showing that all cell compartments were quantified. In the
LCMannotated set several proteins showedmultiple organelle
Figure 4 e Hierarchical clustering and differential protein abundance
of 4-protein predictor. Samples in the training set (n [ 56) were
hierarchically clustered based on 99 differentially abundant proteins (t
test p value< 0.05). Log10 intensities of differentially abundant
proteins constituting the predictor for tamoxifen treatment outcome
are shown in scatter dot plots. Eight poor and four good outcome
patients were misclassified (A). Three out of four proteins, CGN
(Uniprot accession number: Q9P2M7; p value [ 0.006), OCIAD1
(Uniprot accession number: Q9NX40; p value< 0.001) and PDCD4
(Uniprot accession number: Q53EL6; p value< 0.001), had higher
abundance in patients with good outcome, whereas G3BP2 (Uniprot
accession number Q9UN86; p value< 0.001) was found more highly
expressed in the poor outcome patient group (B).
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showed the highest degree of overlap with 249 (12.70%) pro-
teins, mostly represented by proteasome subunits (e.g.
PSME3) and proteins involved in RNA binding (e.g. RBM3,
HNRNPA1). A small number of multi-compartmentalized pro-
teins was constituted by vesicular transport components be-
tween the endoplasmic reticulum and the Golgi apparatus
(n ¼ 39; 1.99%) such as SEC23A. A subset of proteins was
also found co-localized in both Golgi and cytoplasm (e.g.
SEC24D). The remaining compartments showed expression
of locally specific proteins (median overlap: 0.59% of total)
such as oxidative chain proteins in the mitochondrion (e.g.
UQCRC1) or DNA replication and repair involved proteins in
the nucleus (e.g. FEN1). These data indicate the capability of
LC-MS coupled to LCM enrichment to assess protein abun-
dances throughout all cellular compartments from minute
amounts of epithelial tumor tissues.
3.3. Analysis of differentially expressed proteins
Due to the fact that the 1960 proteins did not clearly discrim-
inate patient groups (Supplemental Figure 2), a more stringent
filter for missing values was therefore applied and candidate
proteins were selected based on their differential abundance
between patient groups. On the panel of filtered 845 quantified
proteins, a Student’s t test was performed to identify 99 pro-
teins that were differentially abundant between good and
poor outcome patients in the training set ( p value < 0.05). Of
these, 50 proteins were found upregulated in the poor
outcome group and 49 displayed higher expression in the
good outcome group (Supplemental Table 6). In order to define
molecular interaction networks between significant mole-
cules, network analysis in IPA was performed. The network
that displayed the most hits comprised proteins involved in
cell growth and proliferation and cell death and survival,
such as CDC37 (upregulated in poor outcome) and PDCD4
(upregulated in good outcome; Supplemental Figure 3).
Several molecules included in the network that were found
upregulated in the poor outcome patient group were involved
in integrin-linked kinase signaling (e.g. ITGB1, CFL1), a key
pathway in cell migration and proliferation, protein transla-
tion (e.g. EIF4G1), and DNA mismatch repair (e.g. MSH2). The
proteins found upregulated in the good outcome group and
comprised in this network were involved in cell cycle (e.g.
KRT18) and cell growth (e.g. NOP58). Although not present
among the significant proteins, Akt and MAPK pathways
constituted the focal point of the network, suggesting their
activation based on their interactors expression levels. IPA
analysis showed that differentially expressed proteins were
involved in cell growth and proliferation and suggested that
actors involved in such pathways may have a key role in
tamoxifen resistance.
3.4. Development of a protein signature predictive of
tamoxifen therapy outcome
Based on the 99 differentially abundant proteins, hierarchical
clustering separated the two patient groups (Figure 4A): 20 out
of 28 predicted good outcome patients were correctly classi-
fied as “Good”, while 24 out of 28 predicted poor outcome
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stringent filtering ( p value < 0.01) 38 proteins remained,
which were included in a multivariate Cox regression model.
Using a step-down approach, we identified a 4-protein signa-
ture that best predicted outcome to tamoxifen treatment.
The signature comprised the following proteins: programmed
cell death 4 (PDCD4; t test p value< 0.001), Cingulin (CGN; t test
p value ¼ 0.006), ovarian carcinoma immuno-reactive antigen
domain containing protein 1 (OCIAD1; t test p value < 0.001)
and Ras-GTPase activating protein-binding protein 2 (G3BP2;
t test p value< 0.001; Table 2 and Table 3). Based on LFQ inten-
sity levels, OCIAD1, CGN and PDCD4 showed a relatively high
abundance in good outcome patients, while G3BP2 was more
highly abundant in the poor outcome group (Figure 4B).
Next, patient scores of the 4-protein predictor were plotted
in a ROC curve to select a cut-off with the highest sensitivity
and specificity at predicting poor outcome (J ¼ 0.740, area un-
der the curve ¼ 0.93, sensitivity ¼ 90.6%, specificity ¼ 83.3%;
Figure 5A). The 4-protein predictor was then validated in the
test cohort through Cox regression and KaplaneMeier ana-
lyses. In both Cox univariate andmultivariate regression anal-
ysis for TTP, the 4-protein signature was significantly
correlated with outcome of tamoxifen therapy (HR ¼ 2.44;
95% CI ¼ 1.30 to 4.54; p value ¼ 0.006) and multivariate
(HR¼ 2.17; 95%CI¼ 1.15 to 4.17; p value¼ 0.017) regression an-
alyses corrected for traditional predictive factors (Table 4). In
Kaplan Meier analysis, patients with predicted poor outcome
had significantly shorter TTP compared to those with a pre-
dicted good outcome (HR ¼ 2.32; 95% CI ¼ 1.29 to 4.17; Log-
rank p value ¼ 0.004; Figure 5B). In the test set, sensitivity,
specificity, positive predicted value (PPV), and negative pre-
dicted value (NPV) in predicting poor outcome patients were
86.7%, 41.5%, 35.1% and 89.5%, respectively.Table 2 e LFQ based identification of 4 proteins in discovery and validat
Protein
ID
Gene
name
Molecular
weight (kDa)
Peptides/Unique
peptidesa
Se
Training Test
Q9P2M7 CGN 136.380 22/22 40/40
Q9UN86 G3BP2 54.120 5/5 8/7
Q9NX40 OCIAD1 27.626 8/8 9/9
Q53EL6 PDCD4 51.735 19/19 18/18
a Ratio between peptides and unique peptides associated to each predic
b Peptides/Unique peptides sequence coverage of each protein sequence
c PEP: represents an estimation of a false identification.
Table 3 e Information on the 4 proteins constituting the predictor for ta
Gene name GO cellular component
CGN Cell junction Cingulin
G3BP2 Cytoplasm Ras GTPase-activating prote
OCIAD1 Endosome, Mitochondrion Ovarian carcinoma immun
PDCD4 Cytoplasm, Nucleus Programmed cell death pro3.5. Immunohistochemical assessment of PDCD4
expression and correlation with TTP
While our tissue proteomics pipeline proved to be successful
in identifying and validating the 4-protein predictor, this tech-
nology is not yet readily available in a clinical setting. There-
fore, we assessed protein expression of PDCD4, G3BP2, CNG,
and OCIAD1 through IHC, a technology that is routinely used
in diagnostic laboratories, in an independent set of formalin-
fixed paraffin-embedded breast cancer tissues incorporated
in a TMA. Normal breast epithelium (i.e. acini and ducts)
and leukocytes displayed expression of all markers except
for CGN,which stained themyoepithelial cell layer only. Blood
vessels displayed expression of all 4 proteins, while overall
low to negative staining was displayed in the stromal
compartment. Examples of comparative IHC analysis of
normal breast tissue, blood vessels, leucocytes and breast car-
cinoma cells are displayed in Supplemental Figure 4AeB.
Strong PDCD4 staining (histo-score  30) was found to be
significantly associated with longer TTP in univariate
(HR¼ 0.75; 95% CI¼ 0.59 to 0.96; p value¼ 0.020) andmultivar-
iate Cox regression analysis (HR ¼ 0.72; 95% CI ¼ 0.57 to 0.92; p
value ¼ 0.009) corrected for traditional predictive factors
(Table 5). PDCD4 stained tissues showing both low or high pro-
tein expression and the KaplaneMeier curve for TTP as a func-
tion of the PDCD4 histo-score are shown in Figure 6A and
Figure 6B, respectively. In logistic regression analyses for clin-
ical benefit or objective response, PDCD4 levels (histo-
score  30 vs. < 30) were not significantly associated with
the type of response (data not shown). OCIAD1, CGN and
G3BP2 stainings showed strong intensities and high quantities
of stained tumor cells in the vast majority of specimens. The
limited dynamic range in staining intensities provedion sets.
quence coverage/Unique sequence
coverage (%/%)b
PEP scorec
Training Test Training Test
22.8/22.8 39.5/39.5 3.63E-133 7.88E-268
16.4/16.4 22.0/19.5 1.61E-34 5.85E-84
32.2/32.2 32.7/32.7 5.35E-146 2.59E-247
49.3/49.3 47.8/47.8 1.24E-225 3.23E-281
tor protein.
.
moxifen therapy outcome.
Protein name Student t p value
3.13 0.006
in-binding protein 2 3.50 <0.001
ogenic antigen domain-containing protein 1 4.15 <0.001
tein 4 3.99 <0.001
Figure 5 e ROC curve of the training set and KaplaneMeier curves
for TTP as a function of predicted outcome in patients in the test set.
Patient outcome scores from the training set were calculated based on
abundance levels of the 4 predictor proteins and protein weights (i.e.
Student t value). The ROC curve was generated and Youden
maximum (J [ 0.740) was chosen as the best discriminatory cutoff
(A). Patient scores were subsequently calculated for patients in the
test set, survival curves were generated for the predicted groups and
differences were assessed with the Log-rank test (B). Acronym: AUC:
area under the curve; HR: hazard ratio; CI: confidence interval.
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and G3BP2 levels with TTP, clinical benefit or objective
response (data not shown).4. Discussion
About half of the recurrent ER positive breast cancer patients
treated with tamoxifen show intrinsic resistance to the drug.Despite many studies describing several mechanisms associ-
ated to tamoxifen resistance and a large amount of markers
associated to patient hormonal treatment outcome, there is
no molecular predictor available in the clinic (Chung and
Baxter, 2012; Droog et al., 2013). Furthermore, the search for
biomarkers in the analysis of clinical specimen is often hin-
dered by tissue heterogeneity, which complicates accurate
measurement of tumor protein abundance. In the light of
this, tissue enrichment technologies offer an invaluable tool
to quantify the proteome of specific cell subpopulations.
Though mechanisms of resistance encompass not only a
plethora of molecular mechanisms, but also different cell
types as stromal ones (den Boon et al., 2015; Jung et al.,
2015), analysis of whole tissue specimens would suffer from
“signal dilution” derived from protein differential expression
in heterogeneous tissues. Furthermore, analysis of microdis-
sected stroma is hindered by the presence of high-
abundance proteins (e.g. collagen family) and often needs
additional protein separation methods. In this perspective,
we have focused only on the epithelial tumor markers
involved in tamoxifen resistance. Having successfully coupled
LCM tissue enrichment with high resolution MS in a
biomarker discovery pipeline (Braakman et al., 2012; Liu
et al., 2014, 2012), we have here developed and validated a 4-
protein signature predicting outcome to tamoxifen treatment
in an independent set of ER positive recurrent breast cancer.
Despite the low amount of material derived from tissue
enrichment compared to whole tissue specimens, a higher
number of proteins was identified and quantified in our LCM
samples (training and test sets, and controls) compared to
the WTL control, suggesting interference from highly abun-
dant proteins (e.g. collagen family) in the latter. Furthermore,
from our global proteomic analysis of our combined training
and test sets we showed that plasma and stromal proteins
contamination was minimized in the LCM derived material
while proteins expressed in subcellular compartments were
enriched. This allowed us to take a unique snapshot of protein
abundance of breast cancer epithelial tissue and to derive
markers specifically involved in tumor cell treatment resis-
tance pathways. From a subset of commonly expressed pro-
teins in our 112 ER-positive breast cancer tissues we
developed and validated a protein signature comprising
PDCD4, CGN, OCIAD1 and G3BP2, which was capable of pre-
dicting tamoxifen treatment outcome in the test set with
86.7% sensitivity, 41.4% specificity, 35.1% PPV and 89.5% NPV
and independently from traditional predictive parameters.
The selection of a large cohort of hormonal-treatment naive
patients allowed us to assess tumor protein abundance directly
related to first line tamoxifen treatment without any expres-
sion changes derived from previous therapies. Furthermore,
the availability of an in-house training and a multi-center test
set enabled us to test the robustness of our predictor in a het-
erogeneous set of samples, reflective of differences in patholog-
ical evaluation and standard of care among medical centers.
While our in-house training set showed almost equal distribu-
tion of patient groups, the multi-center cohort comprised a
high number of good outcome patients, which could be
explained by different grading systems used in local hospitals.
To transfer our findingsmore easily to a clinical setting, we also
performed IHC staining on an independent cohort of ER-
Table 4 e Univariate and multivariate Cox regression analysis for time to progression.
Factors Hazard
ratio
Univariate
95% CI
p value Hazard
ratio
Multivariate
95% CI
p value
4 protein predictor score
High 1.00 1.00
Low 2.44 1.30e4.54 0.006 2.17 1.15e4.17 0.017
Age
55 years 1.00 1.00
>55 years 0.44 0.23e0.86 0.017 0.55 0.28e1.08 0.083
Disease free interval
12 months 1.00
>12 months 0.63 0.30e1.31 0.213
Dominant site of relapse Overall p
Loco-regional 1.00 0.270
Bone 0.89 0.30e2.68
Visceral 0.68 0.22e2.09
Bone and other 0.45 0.14e1.40
PgR
Negative 1.00
Positive 0.57 0.32e1.00 0.052
Acronym: PgR: progesterone receptor.
Table 5 e Univariate and multivariate Cox regression analysis for time to progression.
Factors Hazard
ratio
Univariate
95% CI
p value Hazard
ratio
Multivariate
95% CI
p value
PDCD4
Low 1.00 1.00
High 0.75 0.59e0.96 0.020 0.72 0.57e0.92 0.009
Age
55 1.00 1.00
>55 0.58 0.45e0.70 <0.001 0.52 0.40e0.67 <0.001
Disease free interval
12 months 1.00 1.00
>12 months 0.73 0.54e0.99 0.042 0.63 0.46e0.87 0.004
Dominant site of relapse Overall p
Loco-regional 1.00 0.310
Bone 1.39 0.91e2.10
Visceral 1.15 0.73e1.81
Bone and other 1.38 0.89e2.13
PgR
Negative 1.00
Positive 0.77 0.59e1.01 0.062
Acronym: PgR: progesterone receptor.
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independent predictivemarker of tamoxifen sensitivity. Never-
theless, the MS based 4-protein signature was a stronger pre-
dictor than the single marker PDCD4, emphasizing the
potential of proteomic technologies in the dissection of tumor
molecular pathways. Still, introduction of high resolution MS
in routine clinical diagnostics remains problematic due to
extensive and laborious sample preparation and relatively
high costs. On the other side, targeted MSmethods offer an ac-
curate tool to detect andquantitate target analytes (i.e. peptides
or metabolites) from biological specimens at a relatively lower
cost, sample processing and measurement times (Grebe and
Singh, 2011; Yassine et al., 2013), and would therefore consti-
tute a more eligible technique for clinical introduction.Pathways analysis on differentially expressed proteins
showed how cell growth and proliferation pathways are key
components in tamoxifen therapy response and resistance.
Akt and MAPK, although not present among differentially
expressed proteins, constituted the center of the molecular
interaction network, showing how cell cycle progression
through estrogen-independent mechanisms can overcome
tamoxifen treatment. Activation of Akt signaling has been
linked to tamoxifen resistance in previous studies (Clark
et al., 2002; Klinge, 2015; Nass and Kalinski, 2015), but other
molecular mechanisms may be involved. In the light of this,
the 4 protein signature not only is capable of discriminating
patients that manifested good and poor outcome to tamoxifen
treatment, butmay also pinpoint othermolecularmechanisms
Figure 6 e PDCD4 immunohistochemical staining of tissue micro-array. Tissue cores showed two different staining patterns that have been
evaluated by histo-score (i.e. Histo-score< 30 and ‡ 30), representing low and high PDCD4 protein expression (A). Patients were categorized
according to histo-score cutoff and TTP was plotted as a KaplaneMeier curve. The Log-rank test was used to test for differences in TTP between
the two survival curves (B). Acronym: HR: hazard ratio; CI: confidence interval.
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which functions both in the nucleus and the cytoplasm
(Lankat-Buttgereit and G€oke, 2009). This protein has already
been described as a tumor suppressor capable of inhibiting
protein synthesis and gene expression by preventing the inter-
action of eukaryotic initiation factor (eIF) 4A1 and eIF4G, and by
binding to target gene transcripts (e.g. MAP4K) in the nucleus,
respectively (Biyanee et al., 2014; H. Yang et al., 2006). The nu-
clear localization of PDCD4 is attributed to Akt phosphoryla-
tion in a PI3K-dependent manner (Palamarchuk et al., 2005).
PDCD4 levels have also been negatively correlated to increased
expression of miR-21 in MCF-7 cells after tamoxifen treatment
(Klinge et al., 2010; Manavalan et al., 2011). CGN is involved in
tight junction formation and it has been described as apotential epithelial differentiation marker in human neopla-
sias (Citi et al., 1991; Paschoud et al., 2007). Together with Para-
cingulin, CNG controls the expression of GATA-4, contributing
to down-regulation of RhoA in cells, a key regulator of cell cycle
progression that displays its function through cytoskeletal re-
organization (Guillemot et al., 2013). OCIAD1 expression has
been suggested as a thyroid cancer biomarker and has been
correlated to distant metastasis formation, since it was found
overexpressed in metastatic ovarian cancer by MS analysis
(Sengupta et al., 2008; Yang et al., 2012). Recent studies have
demonstrated that OCIAD1 directly interacts with STAT3 and
aids in its activation, though whether this leads to activation
of the tumor suppressor pathway or the oncogenic one still re-
mains unclear (Lee et al., 2012; Musteanu et al., 2010; Sinha
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 2 4e3 9 37et al., 2013). G3BP2 has been shown to be involved in stress
granule formation along with its relative G3BP1, as well as in
mRNA binding and gene expression regulation. G3BP1 protein
has been shown to have a distinct role in breast cancer cell pro-
liferation by stabilizing mRNA molecules, but its homologue
G3BP2was not associated to any of these characteristics, keep-
ing the function of this protein still ambiguous (Kociok et al.,
1999; Matsuki et al., 2013;Winslow et al., 2013).With the excep-
tion of OCIAD1, no studies observed a correlation between
levels of PDCD4, G3BP2, or CGN and patient survival or therapy
response in clinical cancers; nonetheless these markers may
play a role in the type of response to tamoxifen in breast can-
cer. The anti-proliferative effects of PDCD4 and CNGmay have
a synergistic role with the anti-estrogenic action of tamoxifen,
which results in the block of cell proliferation. Due to its rela-
tively high expression in good outcome patients, OCIAD1
may activate the tumor suppressor role of STAT3 in ER positive
breast cancer patients, further inhibiting proliferation. On the
other hand, expression of G3BP2 could actually counteract
tamoxifen action by stabilizing mRNAs of estrogen-
responsive elements aswell as the ones of ER unrelated growth
factors.5. Conclusions
We hereby demonstrate that LCM coupled to high resolution
LC-MS not only enables the proteomic analysis of pure cell
subpopulations, but it also provides a powerful tool for
biomarker discovery studies. This allowed us to delve into
the breast cancer proteome and to generate and validate a
signature predictive of tamoxifen therapy outcome in recur-
rent ER-positive breast cancer. In addition, a technical vali-
dation through IHC verified that PDCD4 is an independent
marker associated with good outcome patients, although it
is difficult to distinguish small changes in protein expres-
sion by IHC. Despite the fact that shotgun LC-MS coupled
to LCM based cell enrichment has shown to be a robust
tool for biomarker discovery, time-consuming sample
preparation and relatively high costs may hinder its intro-
duction into a clinical setting. In the light of this, targeted
LC-MS methods such as multiple reaction monitoring would
be suited to fill this gap, given the fact that accurate
quantification of target analytes can be performed at lower
costs with reasonable optimization times and in a multi-
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